Barclays
AMRI

Barclays’s Albany Molecular Research Inc AMRI Stock Holding History

Barclays’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,000
Closed -$130K – 7270
2017
Q2 		$130K Buy
+6,000
New +$109K ﹤0.01% 4728
2016
Q4 		– Sell
-900
Closed -$15K – 7033
2016
Q3 		$15K Sell
900
-2,000
-69% -$29.6K ﹤0.01% 5630
2016
Q2 		$39K Buy
2,900
+900
+45% +$13.1K ﹤0.01% 4974
2016
Q1 		$30K Hold
2,000
– – ﹤0.01% 5055
2015
Q4 		$38K Buy
+2,000
New +$38K ﹤0.01% 4950
2015
Q2 		– Sell
-900
Closed -$15K – 7351
2015
Q1 		$15K Sell
900
-3,500
-80% -$59.6K ﹤0.01% 6002
2014
Q4 		$70K Buy
4,400
+600
+16% +$11K ﹤0.01% 5462
2014
Q3 		$84K Buy
3,800
+2,400
+171% +$49.1K ﹤0.01% 5468
2014
Q2 		$28K Buy
+1,400
New +$23.7K ﹤0.01% 6335

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Barclays's AMRI Position: Q3 2017 in Review

Barclays sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 122,925 shares — an estimated $2.67M sold.

Barclays first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $2.67M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Barclays reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Barclays sold 122,925 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.67M.
  • Barclays first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
  • Barclays's Albany Molecular Research Inc position peaked at $2.67M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Barclays's 13F filing for Q3 2017, filed 14 Nov 2017.